Safety and Efficacy of Intravenous Recombinant Tissue Plasminogen Activator Administered in the 3- to 4.5-hour Window in Korea

IV-TPA treatment can be safely and efficaciously administered to eligible Korean patients up to the extended time window of 4.5 hours. However, efforts to expedite the treatment should not be neglected.